BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32011328)

  • 1. Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey.
    Barman HA; Özcan S; Atıcı A; Özgökçe C; Öztürk A; Kafalı AE; Çakar NE; Tavşanlı ME; Küçük M; Şahin I; Okuyan E
    Anatol J Cardiol; 2020 Jan; 23(2):79-85. PubMed ID: 32011328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy.
    Kim WS; Kim HS; Shin J; Park JC; Yoo HW; Takenaka T; Tei C
    J Korean Med Sci; 2019 Feb; 34(7):e63. PubMed ID: 30804731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis).
    Güzel T; Çağlar FNT; Ekici B; Kış M; Öztaş S; Öz A; Gök G; Kolak Z; Akşit E; Sarıca SA; Bayrak M; Birdal O; Uğuz B; Gitmez M; Berk Gİ; Oğuz M; Çalık AN; Kılıç S; Zoghi M; Ergene AO
    Int J Cardiovasc Imaging; 2023 Jun; 39(6):1143-1155. PubMed ID: 36920623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.
    Terryn W; Deschoenmakere G; De Keyser J; Meersseman W; Van Biesen W; Wuyts B; Hemelsoet D; Pascale H; De Backer J; De Paepe A; Poppe B; Vanholder R
    Int J Cardiol; 2013 Sep; 167(6):2555-60. PubMed ID: 22805550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
    Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
    PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism?
    Aladağ N; Ali Barman H; Şipal A; Akbulut T; Özdemir M; Ceylaner S
    Balkan J Med Genet; 2023 Jul; 26(1):43-50. PubMed ID: 37576794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
    Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS).
    Palecek T; Honzikova J; Poupetova H; Vlaskova H; Kuchynka P; Golan L; Magage S; Linhart A
    J Inherit Metab Dis; 2014 May; 37(3):455-60. PubMed ID: 24173410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
    Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
    Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.
    Kubo T; Ochi Y; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yoshimitsu M; Higuchi K; Takenaka T; Nakajima K; Togawa T; Tsukimura T; Sano S; Tei C; Sakuraba H; Kitaoka H
    J Cardiol; 2017 Jan; 69(1):302-307. PubMed ID: 27554049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective investigation to establish new screening approach for the detection of patients at high risk of Fabry disease in male left ventricular hypertrophy patients.
    Kubo T; Amano M; Takashio S; Okumura T; Yamamoto S; Nabeta T; Oikawa M; Kurisu S; Ochi Y; Sugiura K; Baba Y; Kuroiwa H; Hirota T; Yamasaki N; Ishii S; Nochioka K; Takeishi Y; Yasuda S; Tsujita K; Izumi C; Kitaoka H
    J Cardiol; 2022 Oct; 80(4):325-331. PubMed ID: 35643740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry Disease Screening in Patients With Kidney Transplant: A Single-Center Study in Turkey.
    Erdogmus S; Kutlay S; Kumru G; Ors Sendogan D; Erturk S; Keven K; Ceylaner G; Sengul S
    Exp Clin Transplant; 2020 Aug; 18(4):444-449. PubMed ID: 32281532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
    Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
    Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Fabry Disease in Familial Mediterranean Fever Patients from Central Anatolia of Turkey.
    Huzmeli C; Candan F; Alaygut D; Bagci G; Akkaya L; Bagci B; Sozmen EY; Kurtulgan HK; Kayatas M
    Biochem Genet; 2016 Aug; 54(4):448-456. PubMed ID: 27105876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.
    Smid BE; van der Tol L; Cecchi F; Elliott PM; Hughes DA; Linthorst GE; Timmermans J; Weidemann F; West ML; Biegstraaten M; Lekanne Deprez RH; Florquin S; Postema PG; Tomberli B; van der Wal AC; van den Bergh Weerman MA; Hollak CE
    Int J Cardiol; 2014 Dec; 177(2):400-8. PubMed ID: 25442977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR).
    Kis M; Dogan Y; Yildirim A; Güzel T; Bekar L; Akhan O; Dogdus M; Harbalıoğlu H; Karabulut D; Soydan E; Zoghi M; Ergene O;
    Acta Cardiol; 2022 Nov; 77(9):836-845. PubMed ID: 36222672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
    Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
    Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
    Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.